fda 503b exclusion
7 Experts Warn About Semaglutide Exclusion
The FDA’s 2026 exclusion of semaglutide and tirzepatide from the 503B bulk list has already raised ingredient costs for midsize compounding chains by up to 15%. This shift forces pharmacies to source new vendors, re-train staff, and redesign inventory plans to keep patients on GLP-1 weight-loss therapy. Medical Disclaimer: